Bambusa is going after unmet needs across skin, respiratory, gastroenterology and autoimmune conditions with long-acting bispecific antibodies. It assembled its lead programs by acquiring assets from a BioNTech SE unit. One candidate is aimed at atopic dermatitis, or eczema, and another targets inflammatory disorders that include respiratory and allergic diseases.
Among the largest holders are Salvia Investment; RA Capital Management; groups associated with German billionaire Thomas Strüngmann; San Francisco-based BVF Partners; KKR-controlled Dawn Biopharma; and Hong Kong-based INCE Capital. Co-founder Shanshan Xu, previously an executive at BioNTech, beneficially owns 21.5% of Bambusa. In November, the company raised $33.1 million in a round joined by existing investors such as RA Capital, Janus Henderson Investors and Dawn Biopharma.
That financing valued the company markedly higher than an $89 million round completed earlier in the year. Bambusa reported $71.5 million in cash and equivalents at the end of June.
Biotech listings test appetite for risk that pays off years out. Market Briefs covers the IPO window free every morning.
Bank of America, Evercore, UBS and Cantor Fitzgerald are leading the IPO. The company plans to list on the Nasdaq Global Select Market under the ticker BBTX.
Early-stage biotech is a swing-for-the-fences game, but this one checks some boxes: experienced backers, recent capital, and programs sourced from BioNTech's orbit. If BBTX lands on Nasdaq, you'll have a clean ticker to track as trial timelines, cash burn, and data readouts start to shape expectations and, potentially, the stock's volatility.
What prices now shapes which treatments get funded next. Get the free Market Briefs daily newsletter and watch it.
